BioNexus Gene Lab Corp. 2023 Form 10-K Summary
Business context and reporting period
BioNexus Gene Lab Corp. filed an audited Form 10-K for the fiscal year ended December 31, 2023. The company operates primarily through two Malaysian subsidiaries: Chemrex, which distributes chemical raw materials, and MRNA Scientific, which provides RNA-based liquid biopsy screening services.
Chemrex generated nearly all consolidated revenue, while MRNA Scientific remains an early-stage diagnostics business. The company is incorporated in Wyoming, conducts substantially all operations in Malaysia and Southeast Asia, and trades on the Nasdaq Capital Market under BGLC.
Financial performance and position
| Metric | 2023 | 2022 | Change/comment |
|---|---|---|---|
| Revenue | $9.771 million | $10.929 million | Down 10.6% |
| Gross profit | $1.329 million | $1.259 million | Up 5.6% |
| Gross margin | 13.6% | 11.5% | Improved |
| Operating loss | $2.594 million | $0.291 million | Material deterioration |
| Net loss | $2.629 million | $0.356 million | Material deterioration |
| Net margin | (26.9%) | (3.3%) | Worsened |
| Operating cash flow | $(1.302) million | $0.552 million | Turned negative |
| Investing cash flow | $(0.383) million | $(0.450) million | Lower cash use |
| Financing cash flow | $5.754 million | $0.108 million | Driven primarily by IPO proceeds |
| Cash and cash equivalents | $5.929 million | $2.119 million | Increased primarily from IPO financing |
| Working capital | $6.416 million | $4.018 million | Improved |
| Total assets | $11.400 million | $8.740 million | Increased |
| Total liabilities | $1.742 million | $2.075 million | Decreased |
Chemrex contributed $9.747 million, or 99.8%, of consolidated revenue, compared with $10.833 million in 2022. MRNA Scientific contributed $24,219, or 0.2%, compared with $95,816 in 2022. Chemrex reported a $267,523 net loss in 2023 versus $275,572 of net profit in 2022; MRNA Scientific reported a $217,146 net loss versus a $240,657 loss.
Reported debt is limited. The balance sheet shows operating lease liabilities of $133,395 and $13,199 owed to a director; the filing does not identify material conventional bank debt. Trade receivables declined to $799,674 after a $1.314 million allowance for expected credit losses. The allowance included a $371,627 opening adjustment from adoption of the current expected credit loss standard and a $942,800 2023 charge.
Material changes versus the prior comparable period
- Revenue declined because of lower Chemrex sales, market competition and reduced selling prices for resin and fiberglass mats in Malaysia.
- Gross profit increased despite lower revenue, reflecting a higher gross margin.
- General and administrative expenses increased to $4.409 million from $1.729 million. The increase included Nasdaq uplisting and public-company compliance costs, business development expenses, share-based compensation, legal and audit fees, and the Chemrex receivables provision.
- Other income increased to $486,036 from $179,283, primarily from dividend income, bank interest and fair-value gains on investments.
- MRNA Scientific revenue fell 75%, which management attributed partly to reduced patient visits to hospitals and clinics following COVID-19 concerns.
- The company completed a July 2023 public offering of 1,437,500 shares at $4.00 per share, producing $5.75 million of gross proceeds and $5.29 million of net proceeds before certain offering expenses. It also issued warrants for 115,000 shares at an exercise price of $4.40 per share, exercisable through July 2028.
- A one-for-twelve reverse stock split became effective in July 2023. Shares issued in connection with the round-up process and stock issued for services increased outstanding shares to 17,667,663 at year-end.
- Stock-based compensation was $511,740, and the company issued shares for professional services and director services.
- Management and board composition changed substantially in December 2023. Su-Leng Tan Lee became CEO and Secretary, and several directors and officers were removed or replaced.
Guidance, outlook, risks and unusual items
Management projects approximately 8% revenue growth from 2023 to 2024, primarily from increased orders from electric-vehicle charging-station manufacturers, and expects growth to stabilize at approximately 7% from 2025 onward. The filing does not provide formal earnings, margin or cash-flow guidance.
Management states that available cash and operating resources are expected to support the current level of operations for at least the next 12 months. However, the company also expects increased spending for marketing, personnel, software development, commercialization and public-company compliance and acknowledges that additional capital may be required. Future equity or debt financing could dilute existing shareholders or impose restrictive terms.
- Chemrex is exposed to cyclical demand, competition, raw-material price volatility, supplier concentration and generally terminable oral customer and supplier arrangements. Its four major suppliers represented 58.5% of 2023 purchases.
- The company has customer concentration at the subsidiary level: Chemrex’s five largest customers represented approximately 25.99% of 2023 revenue.
- MRNA Scientific’s biomarkers have not undergone clinical trials meeting U.S. or European regulatory standards. Market acceptance, regulatory requirements, reimbursement and commercialization remain uncertain.
- The company has no product or service liability insurance for MRNA Scientific’s diagnostic activities and states that Chemrex also faces potential product liability exposure.
- The company relies substantially on trade secrets, know-how and proprietary software and has no patents or copyrights disclosed for its core diagnostics technology.
- Operations are exposed to Malaysian regulatory changes, foreign-exchange fluctuations, political and economic conditions, data privacy obligations and cybersecurity incidents. No material cybersecurity incident was identified in 2023.
- The filing reports no material pending litigation. A post-year-end supplier dispute involves a contract valued at approximately $109,000, with a without-prejudice settlement offer of approximately $76,000 under review.
The audited financial statements received an unqualified opinion. The auditor identified allowance for expected credit losses on trade receivables as a critical audit matter. Management reported effective disclosure controls and effective internal control over financial reporting; the external auditor was not engaged to provide an opinion on internal control effectiveness.
The filing contains an inconsistency in the MD&A: one table reports a 2023 operating loss of $2.965 million, while the audited statement of operations reports a loss from operations of $2.594 million. The audited financial statements appear to be the more authoritative figure.
Important facts for investors to verify
- Confirm the audited balance sheet, cash-and-equivalents composition and actual availability of the $5.929 million reported at year-end.
- Assess whether Chemrex can restore revenue and profitability after the 10.6% revenue decline and 2023 operating loss.
- Review the $1.314 million receivables allowance, customer aging, collections and the impact of the CECL adoption adjustment.
- Determine how much of the IPO proceeds remains and how rapidly cash is being consumed by operating losses and planned expansion.
- Evaluate MRNA Scientific’s limited revenue base, clinical validation status, regulatory exposure and ability to obtain broader healthcare adoption.
- Review dilution from the IPO, service shares, director shares, reverse-split round-up shares and the 115,000 underwriter warrants.
- Reconcile the MD&A operating-loss discrepancy and other inconsistencies in management and financial disclosures.
- Monitor the post-year-end supplier dispute and any related recovery or settlement.
- Review the company’s lack of diagnostic product-liability insurance and the adequacy of other insurance coverage.